An insulin pen with a needle on a white surface, partially with a blue cap nearby.

Tirzepatide

Tirzepatide is a medication used to treat type 2 diabetes. It belongs to a class of drugs known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Tirzepatide works by stimulating both GIP and GLP-1 receptors, leading to improved glycemic control and weight management in patients with type 2 diabetes. It is administered as a once-weekly injection and is often used in combination with other diabetes medications to achieve optimal blood sugar control.

Book Now

 FAQs

  • Tirzepatide is a dual-action injectable medication that mimics GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—two natural hormones involved in blood sugar control and appetite regulation. This dual action helps improve insulin sensitivity, reduce appetite, and support weight loss while maintaining better blood glucose levels.

    • Significant weight loss in individuals with or without diabetes

    • Improved blood sugar control in type 2 diabetes

    • Reduced appetite and food cravings

    • Supports cardiometabolic health

    • Once-weekly dosing for convenience and compliance

  • Tirzepatide is administered as a once-weekly subcutaneous injection, typically on the same day each week. Your provider will start you at a low dose and gradually increase it to improve tolerance and minimize side effects.

  • Tirzepatide may not be appropriate for everyone. Individuals with a history of pancreatitis, medullary thyroid cancer, or certain gastrointestinal conditions may not be candidates. A thorough evaluation by your provider is essential.

  • Common side effects include:

    • Nausea

    • Diarrhea or constipation

    • Decreased appetite

    • Fatigue

    • Indigestion

    These are usually mild and improve over time. More serious but rare side effects include pancreatitis, gallbladder issues, or thyroid tumors. Your provider will monitor you closely throughout treatment.

  • Yes. Clinical trials show significant weight reduction, with many patients losing 15–20% or more of their body weight when combined with a healthy diet and exercise. It’s FDA-approved for type 2 diabetes and under review/available off-label for weight management in non-diabetic patients.

  • Yes. Long-term studies have shown that Tirzepatide is generally safe and effective when used under medical supervision, especially when accompanied by lifestyle changes and regular monitoring.

  • Yes, Tirzepatide can be used alongside other medications like metformin, SGLT2 inhibitors, or insulin, though adjustments may be needed to avoid low blood sugar (hypoglycemia). Your provider will guide your medication regimen.

  • Most patients begin to notice reduced appetite and modest weight loss within a few weeks. Blood sugar improvements and more significant weight changes are typically observed over 8–12 weeks and continue with consistent use.